Monoclonal Antibodies for Louisiana residents who are COVID-19 positive
Monoclonal antibodies (or mAb) have been authorized by the FDA to treat patients with mild to moderate COVID-19. The treatments are done by intravenous (IV) infusion in an outpatient setting and require a referral from the patients’ physician or clinic.
These antibodies are produced in a laboratory to mimic the human immune system response to infection. These man-made drugs block the COVID-19 virus from attaching to and entering human cells, thus neutralizing the virus that causes COVID-19.
- Fact Sheet: Louisiana Department of Health Monoclonal Antibody Treatment for COVID-19
- Questions and Answers
- Health Alert Network Message: 12/23/2020
- CDC: Monoclonal Antibodies: Treatments Your Healthcare Provider Might Recommend if You Are Sick
- CDC: Spreading the Word on the Benefits of Monoclonal Antibodies for COVID-19
- FDA Authorizes Monoclonal Antibody for Treatment of COVID-19
- Fact Sheet for Health Care Providers: EUA of Bamlanivimab
- Fact Sheet for Health Care Providers: EUA of Casirivimab and Imdevimab